Dual antiplatelet therapy in peripheral arterial disease and after peripheral percutaneous revascularization

Journal of Invasive Cardiology

Volumn 24, Issue 12, 2012, Pages 679-684

  Hanna, Elias B ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carotid; Dual antiplatelet therapy; Iliac; Percutaneous intervention; Peripheral arterial disease; Stent; Superficial femoral artery

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PLACEBO; RAPAMYCIN;

CAROTID ARTERY; CEREBROVASCULAR ACCIDENT; DRUG ELUTING STENT; HUMAN; ILIAC ARTERY; LOW DRUG DOSE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL PERCUTANEOUS REVASCULARIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; REVIEW; STENT; SUPERFICIAL FEMORAL ARTERY;

ASPIRIN; ENDOVASCULAR PROCEDURES; HEMORRHAGE; HUMANS; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STENTS; STROKE; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84871330789     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71(3 510-515
2. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47(5 921-929
3. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease. Circulation. 2006;113(11 e465-e520
4. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16 1706-1717
5. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19 1982-1988
6. Cacoub PP, Bhatt DL, Steg PG, et al. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30(2 192-201
7. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH Randomised, double-blind, placebo-controlled trial Lancet. 2004;364(9431 331-337
8. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM; FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER A randomised controlled pilot trial. Lancet Neurol. 2007;6(11 961-969
9. Holm J, Arfvidsson B, Jivegard L, et al. Chronic lower limb ischemia. A prospective randomized controlled study comparing the 1-year results of vascular surgery and percutaneous transluminal angioplasty. Eur J Vasc Surg 1991;5(5 517-522
10. Wilson SE, Wolf GL, Cross AP. Percutaneous transluminal angioplasty versus operation for peripheral arteriosclerosis. Report of a prospective randomized trial in a selected group of patients. J Vasc Surg. 1989;9(1 1-9
11. Tetteroo E, van deer Graaf Y, Bosch JL, et al. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group. Lancet. 1998;351(9110 1153-1159
12. Dyet JF, Gaines PA, Nicholson AA, et al. Treatment of chronic iliac artery occlusions by means of endovascular stent placement. J Vasc Interv Radiol. 1997;8(3 349-353
13. Rzucidlo EM, Powell RJ, Zwolak RM, et al. Early results of stent-grafting to treat diffuse aortoiliac occlusive disease. J Vasc Surg. 2003;37(6 1175-1180
14. Henry M, Amor M, Ethevenot G, et al. Percutaneous endoluminal treatment of iliac occlusions: Long term follow-up in 105 patients. J Endovasc Surg. 1998;5(3 228-235
15. Scheinert D, Schroder M, Ludwig J, et al. Stent-supported recanalization of chronic iliac occlusions. Am J Med. 2001;110(9 708-715
16. Mwipatayi BP, Thomas S, Wong J, et al. A comparison of covered versus bare expandable stents for the treatment of aortoiliac occlusive disease. J Vasc Surg. 2011;54(6 1561-1570
17. Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL Multicentre, randomized controlled trial. Lancet. 2005;366(9501 1925-1934
18. Henry M, Amor M, Beyar I, et al. Clinical experience with a new nitinol self-expanding stent in peripheral artery disease. J Endovasc Surg. 1996;3(4 369-379
19. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354(18 1879-1888
20. Sabeti S, Mlekusch W, Amighi J, Minar E, Schillinger M. Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther. 2005;12(1 6-12
21. Lugmayr HF, Holzer H, Kastner M, Riedelsberger H, Auterith A. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: A midterm follow-up. Radiology. 2002;222(1 37-43
22. Laird JR, Katzen BT, Scheinert DT, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery. Twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3(3 267-276
23. Duda SH, Bosiers M, Lammers J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: Long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13(6 701-710
24. Dake M, Ansel G, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare-metal stents in femoropopliteal disease: Twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4(5 495-504
25. Ansel G. Interim results of the VIBRANT trial. Presented at Vascular Interventional Advances, Oct. 20-23, 2011; Las Vegas, Nevada
26. Zeller T, Rastan A, Sixt S, et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol. 2006;48(8 1573-1578
27. Iida O, Uematsu M, Soga Y, et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv. 2011;78(4 611-617
28. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropolpliteal stenting. J Am Coll Cardiol. 2005;45(2 312-315
29. Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: Six-month results. Circulation. 2002;106(12 1505-1509
30. Nakazawa G, Finn AV, Vorpahl M, et al. Incidence and predictors of drug-eluting stent fracture in human coronary artery. A pathologic analysis. J Am Coll Cardiol. 2009;54(21 1924-1931
31. Walters TK, Mitchell DC, Wood RF. Low-dose aspirin fails to inhibit increased platelet reactivity in patients with peripheral vascular disease. Br J Surg. 1993;80(10 1266-1268
32. Bauermeister G. Endovascular stent-grafting in the treatment of superficial femoral artery occlusive disease. J Endovasc Ther. 2001;8(3 315-320
33. Schachinger V, Hamm CW, Muzel T, et al. A randomized trial of polytetrafluoroethylene-membrane covered stent in aortocoronary saphenous venous grafts. J Am Coll Cardiol. 2003;42(8 1360-1369
34. Stankovic G, Colombo A, Presbito P, et al. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous veins grafts trial. Circulation. 2003;108(1 37-42
35. Fritschy WM, Kruse RR, Frakking TG, et al. Performance of ePTFE-covered endograft in patients with occlusive disease of the superficial femoral artery: A three-year clinical follow-up study. J Cardiovasc Surg. 2010;51(6 783-790
36. Belch JJ, Dormandy J, Biasi BM, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR trial). J Vasc Surg. 2010;52(4 825-833
37. Soga Y, Yokoi H, Kawasaki T, et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol. 2009;53(1 48-53
38. Soga Y, Lida O, Hirano K, et al. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol. Catheter Cardiovasc Interv. 2012;79(4 541- 548. 2011, July 29 (Epub ahead of print).
39. Morishita R. A scientific rationale for the CREST trial results: Evidence for the mechanism of action of cilostazol in restenosis. Atheroscler Suppl. 2005;6(4 41-46
40. Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004;351(15 1493-1501
41. Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med. 2006;355(16 1660-1671
42. Ringleb PA, Allenberg J, Bruckmann H, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: A randomised non-inferiority trial. Lancet. 2006;368(9543 1239-1247
43. International Carotid Stenting Study Investigators. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (international carotid stenting study An interim analysis of a randomised controlled trial. Lancet. 2010;375(9719 985-997
44. Brott TG, Hobson RW II, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363(1 11-23
45. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7 494-502
46. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA. 2002;288(19 2411-2420
47. Valgimigli M. PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study. Presented at European Society of Cardiology Congress, August 2011, Paris, France.